British scientists are developing the world’s first lung cancer vaccine. The DNA strand that will be used to instruct the immune system to hunt for and delete red flag proteins—proteins that appear on lung cancer cells and may contain mutations that could lead to cancer—will be the way by which it operates. Sky News reports that scientists from the University of Oxford, the Francis Crick Institute, and University College London (UCL) are collaborating on producing the vaccine. According to the outlet, the LungVax vaccine will be similar to the Oxford-AstraZeneca Covid vaccine.
LungVax? : The group intends to develop three thousand doses of the vaccine
The group intends to develop three thousand doses of the vaccine, which identifies and removes red flag proteins, also known as neoantigens. Lung cancer is the most frequent cancer in Britain, accounting for approximately 50,000 cases and 35,000 deaths per year. Smoking is a factor in seven out of 10 cases. Individuals aged 55 to 74 who smoke or have formerly smoked are at high risk. ‘Less than 10% of lung cancer patients survive their illness for ten years or more, according to Professor Mariam Jamal-Hanjani of UCL and the Francis Crick Institute, who will lead the LungVax clinical trial.
“This research complements existing efforts through lung health checks to detect lung cancer earlier in people who are at greatest risk,” she said. The researcher said that it has the potential to treat 90% of lung malignancies. “LungVax will not replace stopping smoking as the best way to reduce your risk of lung cancer,” stated Dr. Mariam. The American Cancer Society defines lung cancer as the uncontrollable proliferation of lung cells. These are two sponge-like organs in your chest that are divided into portions known as lobes.